Cerevance’s Phase 2 Trial Recruiting Patients to Test Oral CVN424 Therapy for Motor Symptoms
Cerevance has initiated a Phase 2 clinical trial to evaluate the safety and efficacy of its oral investigational therapy…
Articles by Alice Melão
Deep Brain Stimulation May Impair Swimming Ability and Increase Risk of Drowning, Case Studies Suggest
Patients who undergo deep brain stimulation to treat Parkinson’s disease may lose their ability to swim, even if…
New Collaboration Will Focus on Developing Parkinson’s Screening Software
Startup company Jesse Medical and researchers from the Royal Melbourne Institute of Technology (RMIT) have agreed to collaborate on…
SleepFit App Can Help Improve Daily Monitoring of Parkinson’s Motor Symptoms, Study Says
A new application for Android tablets, called SleepFit, may help to monitor the daily progression and response to treatment of…
World Neurology Congress Spotlights the Impact of Climate Change and Environmental Risk Factors on Brain Health
The impact of climate change and environmental risk factors on brain health was spotlighted at this year’s World Congress of…
Diabetics Being Treated with Thiazolidinediones May Be at Lower Risk of Parkinson’s, Study Suggests
People with type 2 diabetes being treated with thiazolidinedione compounds, such as Actos (pioglitazone) and Avandia (rosiglitazone),…
Veterans with PTSD or Brain Injury at Risk of Sleep Disorder That Might Signal Parkinson’s, Study Finds
Military veterans with post-traumatic stress disorder (PTSD) or who experienced a traumatic brain injury have more than double the risk…
Mutations in Alpha-Synuclein Speed Protein Clumping in Familial Parkinson’s and Affect Severity, Study Finds
A detailed analysis of alpha-synuclein — a key protein involved in Parkinson’s — revealed how variants of this…
Genetic Parkinson’s More Common Than Thought, Global Survey Reveals
Cases of inherited Parkinson’s disease may be more frequent than previously reported, results from an online global survey suggest. The…
Potential Treatment to Prevent Toxic Protein Clumping Enters Phase 1 Trial, Yumanity Announces
Yumanity Therapeutics announced the start of a Phase 1 clinical study in healthy volunteers that will assess the safety and…